Search Results - "Jethwa, S."

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN by Melichar, B., Bracarda, S., Matveev, V., Alekseev, B., Ivanov, S., Zyryanov, A., Janciauskiene, R., Fernebro, E., Mulders, P., Osborne, S., Jethwa, S., Mickisch, G., Gore, M., van Moorselaar, R.J.A., Staehler, M., Magne, N., Bellmunt, J.

“…Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-α2a (IFN; 9 MIU tiw) in first-line metastatic renal…”
Get full text

Adverse reactions to tattoos by Jethwa, Ankeet S

Get full text

459 Clinical Utility of Pharmacogenetic Tests When Prescribing Antidepressant Therapy for Depression, A Systematic Review and Meta-analysis of Randomised Controlled Trials by Jethwa, S, Almomani, H, Donyai, P

“…Abstract Introduction Pharmacogenetic testing when prescribing medicines has the potential to reduce harmful side effects, optimise treatment, and improve…”
Get full text

False‐positive myeloperoxidase binding activity due to DNA/anti‐DNA antibody complexes: a source for analytical error in serologic evaluation of anti‐neutrophil cytoplasmic autoantibodies by Jethwa, H. S., Nachman, P. H., Falk, R. J., Jennette, J. C.

“…Anti‐myeloperoxidase antibodies (anti‐MPO) are a major type of anti‐neutrophil cytoplasmic antibody (ANCA). While evaluating anti‐MPO monoclonal antibodies…”
Get full text

Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa by Šedivá, Anna, Bartůňková, Jiřina, Bartošová, Jana, Jennette, Charles, Falk, Ronald J., Jethwa, Hitendra S.

“…Antineutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability-increasing protein (BPI) were repeatedly found in cystic fibrosis (CF)…”
Get full text

7123 First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival by Melichar, B, Bracarda, S, Bellmunt, J, Ravaud, A, Negrier, S, Jethwa, S, Escudier, B

Get full text

7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN by Bracarda, S, Bellmunt, J, Negrier, S.N, Melichar, B, Ravaud, A, Jethwa, S, Sneller, V, Escudier, B

Get full text

All convulsions in labour are not attributable to pre-eclampsia by Jethwa, S., Catling, S.

Get full text

1031P ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors by Calvo, E., Joerger, M., Läubli, H., Lopez, J.S., Alonso, G., Corral de la Fuente, E., Hess, D., König, D., Perez, V., Gasal, E., Jethwa, S., Di Blasi, D., Garralda, E.

Get full text

749P ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II study by Läubli, H., Alonso, G., Lopez, J.S., Calvo, E., Joerger, M., Perez, V., Di Blasi, D., Nair, A., Richter, K., Huber, C., Mouton, J., Costanzo, S., Jethwa, S., Bucher, C.M., Garralda, E.

Get full text

Comparison of molecular and microscopic techniques for detection of Treponema pallidum in genital ulcers by JETHWA, H. S, SCHMITZ, J. L, DALLABETTA, G, BEHETS, F, HOFFMAN, I, HAMILTON, H, LULE, G, COHEN, M, FOLDS, J. D

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Restriction in V kappa gene use and antigen selection in anti-myeloperoxidase response in mice by Jethwa, H S, Clarke, S H, Itoh-Lindstrom, Y, Falk, R J, Jennette, J C, Nachman, P H

“…Anti-neutrophil cytoplasmic Abs, directed primarily toward myeloperoxidase (MPO) and proteinase 3, are detected in the majority of patients with distinct forms…”
Get full text

Navigating dermatology training in the United Kingdom by Krishna, Sreedhar, Jethwa, Ankeet

“…[...]there a number of new dermatology courses available, which are briefly summarised as follows: Key points Demand for dermatologists is increasing and looks…”
Get full text

Randomised controlled trials and alternative therapy by Krishna, Sreedhar, Jethwa, Ankeet

Get full text

BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC) by Melichar, B., Bracarda, S., Matveev, V., Rusakov, I., Kaprin, A., Zyryanov, A., Janciauskiene, R., Fernebro, E., Mickisch, G. H., Gore, M. E., Schulze, A., Jethwa, S., Sneller, V., Mulders, P., Bellmunt, J.

“…Abstract only…”
Get full text

Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) by Escudier, B. J., Bellmunt, J., Negrier, S., Melichar, B., Bracarda, S., Ravaud, A., Golding, S., Jethwa, S.

“…Abstract only 5020 Background: In the AVOREN trial, BEV (Avastin) + IFN significantly improved PFS and ORR compared with placebo + IFN in pts with mRCC…”
Get full text

Restriction in V{kappa} Gene Use and Antigen Selection in Anti-Myeloperoxidase Response in Mice by Jethwa, Hitendra S, Clarke, Stephen H, Itoh-Lindstrom, Yoshie, Falk, Ronald J, Jennette, J. Charles, Nachman, Patrick H

Get full text

Anti-neutrophil cytoplasmic antibody (ANCA) target antigens, disease associations, and laboratory testing by Jethwa, Hitendra S., Falk, Ronald J., Jennette, J. Charles

Get full text